Cargando…

Guidelines or guidance for better idiopathic pulmonary fibrosis management?

Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic interstitial lung disease with a relentlessly progressive course and fatal outcome. Guidelines summarizing the current evidence and providing evidence-based recommendations for the treatment of rare diseases such as IPF are important since indiv...

Descripción completa

Detalles Bibliográficos
Autor principal: Behr, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748484/
https://www.ncbi.nlm.nih.gov/pubmed/26860906
http://dx.doi.org/10.1186/s12916-016-0567-9
_version_ 1782415124516044800
author Behr, Jürgen
author_facet Behr, Jürgen
author_sort Behr, Jürgen
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic interstitial lung disease with a relentlessly progressive course and fatal outcome. Guidelines summarizing the current evidence and providing evidence-based recommendations for the treatment of rare diseases such as IPF are important since individual physicians often have limited experience. Nevertheless, the available evidence is often scarce and, therefore, evidence-based recommendations are prone to being vague or with low confidence, thus creating uncertainty instead of guidance. Moreover, the effect of guidelines themselves on clinical practice has not been sufficiently evaluated. On the other hand, expert opinion may be biased and lead to the misinterpretation of evidence, resulting in misleading recommendations and a potential harm to patients. This editorial focuses on the advantages and disadvantages of evidence-based guidelines and professional experience in the context of a rare disease such as IPF and tries to assess the optimum combination of both approaches. Please see related commentary articles: http://dx.doi.org/10.1186/s12916-016-0562-1 and http://dx.doi.org/10.1186/s12916-016-0563-0
format Online
Article
Text
id pubmed-4748484
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47484842016-02-11 Guidelines or guidance for better idiopathic pulmonary fibrosis management? Behr, Jürgen BMC Med Editorial Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic interstitial lung disease with a relentlessly progressive course and fatal outcome. Guidelines summarizing the current evidence and providing evidence-based recommendations for the treatment of rare diseases such as IPF are important since individual physicians often have limited experience. Nevertheless, the available evidence is often scarce and, therefore, evidence-based recommendations are prone to being vague or with low confidence, thus creating uncertainty instead of guidance. Moreover, the effect of guidelines themselves on clinical practice has not been sufficiently evaluated. On the other hand, expert opinion may be biased and lead to the misinterpretation of evidence, resulting in misleading recommendations and a potential harm to patients. This editorial focuses on the advantages and disadvantages of evidence-based guidelines and professional experience in the context of a rare disease such as IPF and tries to assess the optimum combination of both approaches. Please see related commentary articles: http://dx.doi.org/10.1186/s12916-016-0562-1 and http://dx.doi.org/10.1186/s12916-016-0563-0 BioMed Central 2016-02-10 /pmc/articles/PMC4748484/ /pubmed/26860906 http://dx.doi.org/10.1186/s12916-016-0567-9 Text en © Behr. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Editorial
Behr, Jürgen
Guidelines or guidance for better idiopathic pulmonary fibrosis management?
title Guidelines or guidance for better idiopathic pulmonary fibrosis management?
title_full Guidelines or guidance for better idiopathic pulmonary fibrosis management?
title_fullStr Guidelines or guidance for better idiopathic pulmonary fibrosis management?
title_full_unstemmed Guidelines or guidance for better idiopathic pulmonary fibrosis management?
title_short Guidelines or guidance for better idiopathic pulmonary fibrosis management?
title_sort guidelines or guidance for better idiopathic pulmonary fibrosis management?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748484/
https://www.ncbi.nlm.nih.gov/pubmed/26860906
http://dx.doi.org/10.1186/s12916-016-0567-9
work_keys_str_mv AT behrjurgen guidelinesorguidanceforbetteridiopathicpulmonaryfibrosismanagement